US · JSPR
Jasper Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Redwood City, CA 94065
- Website
- jaspertherapeutics.com
Price · as of 2024-12-31
$0.93
Market cap 22.43M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $98.60 | ||||
| 2020 | $99.41 | ||||
| 2021 | $33.90 | ||||
| 2022 | $17.30 | ||||
| 2023 | $27.55 | ||||
| 2024 | $5.37 |
AI valuation
Our deep-learning model estimates Jasper Therapeutics, Inc.'s (JSPR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.93
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| JSPR | Jasper Therapeutics, Inc. | $0.93 | 22.43M | — | — | — | — | -1.10 | 1.27 | — | -0.11 | — | 1.27 | 0.00% | — | — | -101.73% | 1104.03% | -81.55% | 0.03 | — | 4.98 | 4.70 | 0.93 | -2087.00% | — | 2067.00% | -80.64% | -4.11 | 914.55% | 0.00% | 0.00% | 0.00% | -0.11 | -0.13 | — | -3.88 |
| BOLD | Boundless Bio, Inc. | $1.16 | 25.97M | — | — | — | — | -0.44 | 0.19 | — | 1.18 | -0.60 | 0.19 | 0.00% | — | — | -554.86% | 73.46% | -38.87% | 0.32 | — | 18.98 | 18.70 | -0.33 | 7342.00% | — | 3346.00% | -220.80% | -7.48 | 63.54% | 0.00% | 0.00% | 0.00% | 1.03 | 1.20 | — | -1.38 |
| BTAI | BioXcel Therapeutics, Inc… | $1.67 | 36.52M | +9,886% | -19% | — | — | -0.14 | -0.09 | 3.77 | -1.85 | — | -0.09 | 5.43% | -2967.56% | -2630.14% | 79.67% | 333.28% | -106.39% | -1.11 | -4.44 | 1.68 | 1.35 | -1.66 | -7610.00% | 6420.00% | -5354.00% | -843.12% | -3.24 | 356.98% | 0.00% | 0.00% | 0.00% | -1.21 | -1.13 | 36.03 | -28.96 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| GBIO | Generation Bio Co. | $5.34 | 35.98M | +46% | -60% | — | — | -0.27 | 0.41 | 1.78 | 0.76 | -40.69 | 0.41 | 100.00% | -715.82% | -661.91% | -91.02% | -912.79% | -43.46% | 1.09 | — | 5.50 | 5.33 | -0.23 | 66.00% | 23692.00% | 5125.00% | -256.40% | -2.53 | -583.12% | 0.00% | 0.00% | 39.99% | 0.39 | 0.62 | -2.82 | -5.24 |
| MURA | Mural Oncology plc | $2.04 | 35.38M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
| NXTC | NextCure, Inc. | $12.72 | 34.09M | — | — | — | — | -0.38 | 0.32 | — | 0.77 | — | 0.32 | 0.00% | — | — | -61.87% | -769.60% | -53.28% | 0.09 | — | 7.50 | 7.20 | 0.40 | -1168.00% | — | -2326.00% | -196.82% | -4.26 | -531.71% | 0.00% | 0.00% | 72.95% | 0.70 | 1.01 | — | -7.28 |
| PSTV | Plus Therapeutics, Inc. | $0.30 | 18.31M | +20,855% | +1,192% | — | — | -0.80 | -1.16 | 1.79 | -1.21 | — | -1.06 | 85.37% | -252.32% | -222.84% | 252.07% | 197.13% | -144.03% | -0.38 | -3.95 | 0.34 | 0.27 | -0.39 | -4481.00% | 1854.00% | -1776.00% | -102.64% | -0.68 | 143.54% | 0.00% | 0.00% | 3.59% | -0.69 | -0.95 | 1.75 | -112.05 |
| QTTB | Q32 Bio Inc. | $4.56 | 56.11M | +726% | — | — | — | -0.57 | 4.77 | — | 0.71 | — | 4.77 | 0.00% | — | — | 53.86% | 62.63% | -68.49% | 3.33 | -220.34 | 4.97 | 4.77 | 1.30 | -6060.00% | -10000.00% | 26286.00% | -250.34% | -4.11 | 64.23% | 0.00% | 0.00% | 311.27% | 0.48 | 0.47 | — | -4.89 |
| SABS | SAB Biotherapeutics, Inc. | $4.10 | 39.19M | +213% | -84% | — | +2,692% | -0.44 | 0.58 | 11.35 | 0.04 | — | 0.58 | -262.41% | -3244.87% | -2579.03% | -81.92% | -519.55% | -53.23% | 0.18 | -134.77 | 2.98 | 2.61 | 0.15 | -5183.00% | -4094.00% | 3679.00% | -230.79% | -4.30 | -419.29% | 0.00% | 0.00% | 0.00% | 0.03 | 0.03 | -0.82 | -6.18 |
| VRCA | Verrica Pharmaceuticals I… | $5.47 | 51.91M | +100% | -56% | — | — | -0.41 | -3.19 | 4.16 | -0.47 | — | -3.19 | 63.79% | -871.25% | -1012.15% | -1546.58% | 907.73% | -112.84% | -4.66 | -7.00 | 1.76 | 1.60 | 0.01 | 0.00% | 4766.00% | 5654.00% | -193.51% | -2.10 | 839.36% | 0.00% | 0.00% | 0.00% | -0.47 | -0.51 | 4.11 | -11.03 |
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
- CEO
- Jeetinder Singh Mahal
- Employees
- 64
- Beta
- 3.09
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.93) − 1 = — (DCF, example).